H

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,803		04/21/2006	Mary J. Champion	D-3150	5915
Frank J Uxa	7590	09/25/200	7	EXAM	INER
4 Ventura				GHALI, ISIS A D	
Suite 300 Irvine, CA 926	18			ART UNIT	PAPER NUMBER
,				1615	
				MAIL DATE	DELIVERY MODE
				09/25/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action

Application No.	Applicant(s)	
10/576,803	CHAMPION, MARY J.	
Examiner	Art Unit	
Isis A. Ghali	1615	

Before the Filing of an Appeal Brief --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 18 September 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. 🔯 The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: The period for reply expires _____months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL . A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of 2. The Notice of Appeal was filed on ___ filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. X For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) X will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 33, 35, 36, 38, 41, 44, 45, 54-59 and 61-65. Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: ISIS GHALI 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). PRIMARY EXAMINER 13.
Other: ___

Isis A Ghali

Primary Examiner Art Unit: 1615

Claims 33, 35, 36, 38, 41,44, 45, 55-59, 61-65 remain rejected under 35 U.S.C. 103(a) as being unpatentable over the presentation prepared by Kobayashi Healthcare, INC.: "Product Concept Test", hereinafter Kobayashi, in view of any of JP2002119529 ('529) or US 6,224,899 ('899).

Claims 33, 35, 36, 38, 41,44, 45, 55-59, 61-65 remain rejected under 35 U.S.C. 103(a) as being unpatentable over JP '529 or US '899 each in view of US 5,730,957 ('957).

The main gist of applicant's argument against the obviousness rejections above is that none of the references teaches method for treating hot flashes comprising placing cooling device comprising water containing gel at a location on the upper back of a women, and the references do not teach instructing the women to place the cooling device at the upper back. Applicant argues that the replacing the cooling device on the upper back provided relief of the hot flashes. Applicants argue that BeKool was located 2007, and not a prior art.

In response to these argument, applicant's attention is directed to the scope of the present claims that are directed method of treating hot flashes comprising the steps of providing one Colin's device, and instructing the patient. The step of providing the cooling device is implied by all the references. Regarding the "instructing step", such a step not patentable limitation in utility application. The instruction to apply the patch, at specific site does not impart patentability to the claims because it is expected that the patch will be applied to the site of origin of hot flashes as disclosed by applicant on page 9, lines 1-5. The references teach treating hot flashes, and applicant failed to show unexpected results obtained from placing the cooling device over the upper back. The prior art devices are capable to perform the same function, therefore rendering the claims obvious. In any event, the package, the instruction, and removing the cooling device from the package are obvious and are evident by the pamphlet provided by "BeKOOL soft gel sheet product", provided. Also the provided pamphlet shows drawing wherein the sheet is applied to the upper back in a woman with hot flashes. BeKool was available since 2003. In considering the disclosure of the reference, it is proper to take into account not only the specific teachings of the reference but also the inferences which one skilled in the art would reasonably be expected to draw therefrom. In re Preda, 401 F.2d 825, 826, 159 USPQ 342, 344 (CCPA 1968). The rational to modify or to combine the prior art does not have to be expressly stated in the prior art; the rational may be expressly or impliedly contained in the prior art or it may be reasoned from knowledge generally available to one of ordinary skill in the art. The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve different problem. It is not necessary that the prior art suggest the combination or modification to achieve the same advantage or result discovered by applicant. In re Linter, 458 F.2d 1013, 173 USPQ 560 (CCPA 1972).

It is well established that the claims are given the broadest interpretation during examination. A conclusion of obviousness under 35 U.S.C. 103 (a) does not require absolute predictability, only a reasonable expectation of success; and references are evaluated by what they suggest to one versed in the art, rather than by their specific disclosure. In re Bozek, 163 USPQ 545 (CCPA 1969)... In the light of the foregoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the claims would have been prima facie obvious within the meaning of 35 U.S.C. 103 (a).

dinghal.